Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Category: Uncategorized

Brivaracetam

Plain-language summaryIntrigue 65 / 100

Brivaracetam, sold as Briviact, is a propyl-substituted analog of levetiracetam with higher SV2A affinity. It is FDA-approved for partial-onset seizures and offers improved tolerability over levetiracetam in some patients. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

51/100

Superior SV2A probe over levetiracetam, FDA-approved, but an incremental advance in well-trodden antiepileptic territory

Look, brivaracetam is a genuinely well-executed optimization of levetiracetam, but “well-executed optimization of a 25-year-old approved drug” is exactly what keeps it out of the 70s. UCB Pharma’s medicinal chemistry work here was solid: the propyl substitution at C4 increases SV2A affinity roughly 15-fold (Kd 0.06 microM versus around 1 microM for levetiracetam), and the selectivity profile is cleaner across potential off-targets. FDA approved it as Briviact in February 2016 for partial-onset seizures, and the phase 3 data are unambiguous. That’s a real accomplishment. The problem, from a research interest perspective, is that the SV2A story is now well-established ground.

SV2A is genuinely interesting biology. Its role in calcium-dependent vesicle priming and the modulation of neurotransmitter release is still being refined at the molecular level – we dont fully understand how SV2A binding translates into the anticonvulsant effect, and that gap is worth filling. Brivaracetam’s tighter, more selective binding makes it a better probe for this work than levetiracetam, which is where we see the real research argument. If your program involves dissecting SV2A function in synaptic terminals or screening SV2A-interacting partners, you want the highest-affinity selective tool available, and brivaracetam wins that contest over the parent compound.

What we like: the behavioral and psychiatric side effect profile is meaningfully improved versus levetiracetam, with lower rates of irritability and depression at equivalent doses. That tells us something real about what those levetiracetam side effects were attributable to, possibly off-target activity that got cleaned up by the analog work. The PK is also clean: oral bioavailability is essentially complete, half-life around 9 hours, hepatic metabolism straightforward via amide hydrolysis and CYP2C19. Good experimental drug properties in a tool compound.

What keeps the score where it is: theres no new indication horizon here. The antiepileptic space for SV2A ligands is as mapped as its going to get for a first-line use case, and brivaracetam entered a market where levetiracetam was already going generic, offering a tolerability advantage in a subset of patients who hit psychiatric side effects. The clinical trials confirmed efficacy nobody doubted. The mechanistic questions that remain around SV2A are addressable with brivaracetam as a pharmacological tool, but that’s a probe use case, not a frontier indication story. Schedule V status makes sourcing and handling about as uncomplicated as a controlled antiepileptic gets.

Honestly, if you’re running SV2A biology and want a pharmacological tool that out-performs levetiracetam on target engagement and selectivity, brivaracetam earns a place on the bench. But it’s not a compound that’s going to redefine what you think is possible in its space.

Novelty

27

Mechanism promise

42

In-category differentiation

48

Evidence quality

77

Translational signal

73

Research bench value

52

Rationale Strong evidence base from multiple phase 3 RCTs and FDA approval boosts evidence and translational scores, but brivaracetam is a 10-year-old analog of a 25-year-old drug operating on a mechanism the field has largely mapped; novelty and differentiation are low, and the primary research argument is probe utility for SV2A biology rather than any frontier indication.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Propyl-substituted pyrrolidinone (high-affinity SV2A ligand)

A propyl-substituted levetiracetam analog with 15-fold higher SV2A affinity, FDA-approved 2016 as Briviact for partial-onset seizures.

Abstract

Brivaracetam (Briviact; UCB-34714; (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide; CAS 357336-20-0; molecular formula C11H20N2O2; molecular weight 212.29) is a propyl-substituted levetiracetam analog developed at UCB Pharma and approved by the FDA in February 2016 as adjunctive therapy for partial-onset seizures. Brivaracetam binds SV2A with approximately 15-fold higher affinity than levetiracetam (Kd 0.06 microM versus 1 microM) and shows higher selectivity for SV2A over other potential targets. The clinical consequence is improved seizure protection at lower doses with a flatter pharmacokinetic-pharmacodynamic relationship. Compared with levetiracetam, brivaracetam shows lower rates of behavioral and psychiatric adverse effects (irritability, depression), which are dose-limiting for some levetiracetam patients. Pharmacokinetics: plasma half-life 9 hours; oral bioavailability essentially complete; metabolism is hepatic via amide hydrolysis and CYP2C19. Approved doses are 50 to 200 mg per day in two divided administrations. Schedule V in the United States.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-034Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Meldonium (Mildronate)

Plain-language summaryIntrigue 68 / 100

Meldonium (Mildronate) is a Latvian-developed compound that inhibits carnitine biosynthesis, shifting cellular metabolism toward glucose-based energy. It is used for ischemic conditions in Eastern Europe. Famous for the 2016 Maria Sharapova doping case. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Mature Soviet-era cardioprotective with real mechanism but geographically siloed evidence base

Look, meldonium is not a boring compound. It’s just a mature one. Ivars Kalvins synthesized it at the Latvian Institute of Organic Synthesis in the 1970s as a structural analog of gamma-butyrobetaine, and the core idea is genuinely elegant: competitively inhibit gamma-butyrobetaine hydroxylase, suppress endogenous carnitine biosynthesis, and force cardiac and skeletal muscle to shift from fatty acid oxidation toward glucose oxidation. Under ischemic conditions that shift matters because glucose oxidation is more oxygen-efficient per ATP generated, and fatty acid oxidation generates disproportionate reactive oxygen species when oxygen delivery is compromised. That’s not trivial pharmacology. We like the mechanism more than we like the evidence base.

The WADA ban in 2016 and the Sharapova case turned meldonium into a household name, and it did generate a burst of Western interest. But most of what we know about clinical efficacy still comes from Latvian, Russian, and Baltic cooperative trials, and the methodological standards of that literature vary substantially. Systematic reviews, including work from Karelis and colleagues trying to contextualize the WADA decision, have noted how difficult it is to evaluate the cardiac endpoint data against contemporary trial design standards. Thats a problem for any serious evidence weighting. The approved indications in Latvia and Russia are real, but regulatory approval in those markets reflects a different evidentiary threshold than FDA or EMA review.

Where meldonium still holds some bench value is metabolic research. If you’re building models of carnitine-dependent fatty acid import into mitochondria, or studying the interplay between FAO and glucose oxidation under hypoxic stress, meldonium is a reasonably clean pharmacological tool. It’s not perfect. The carnitine depletion it drives can produce off-target effects over longer exposure windows, and dosing dynamics in rodent models don’t translate cleanly to primate physiology. But as a probe of the gamma-butyrobetaine hydroxylase axis specifically, it doesn’t have many competitors.

The neuroprotection angle is worth watching. Some investigators have framed the cerebrovascular indication as a glucose-oxidation story in neural tissue, and there are a few small trials in cognitive decline populations in Eastern Europe that warrant scrutiny. We think this is the most underexplored corner of the meldonium literature in Western research contexts, but the evidence there is even thinner than the cardiac data.

Honestly, the compound sits in a frustrating middle zone. The mechanism is real, the human signal is real, and the tool utility is genuine. But five decades of development in a geographically restricted research ecosystem, with weak replication outside that ecosystem, keeps it off the frontier. If you’re already running a metabolic cardioprotection or hypoxia-response program, meldonium deserves a place in your reference pharmacology. As a primary research focus right now? The case is harder to make.

Novelty

22

Mechanism promise

40

In-category differentiation

48

Evidence quality

47

Translational signal

50

Research bench value

42

Rationale Meldonium scores modestly because it’s a 1970s compound with a clean, well-characterized mechanism that’s genuinely interesting for ischemia and metabolic research, but the evidence base is overwhelmingly concentrated in Latvian and Russian institutions with minimal Western replication, and the clinical indication space it targets is crowded with better-validated alternatives. The WADA notoriety brought attention but not new mechanistic depth.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Carnitine biosynthesis inhibitor

A Latvian-developed carnitine biosynthesis inhibitor used clinically for ischemic heart disease, banned by WADA in 2016 after high-profile athlete cases.

Abstract

Meldonium (Mildronate; 3-(2,2,2-trimethylhydrazinium)propionate; CAS 76144-81-5; molecular formula C6H14N2O2; molecular weight 146.19) is a synthetic structural analog of gamma-butyrobetaine, the precursor of L-carnitine, developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. The compound competitively inhibits gamma-butyrobetaine hydroxylase, reducing endogenous carnitine biosynthesis and shifting cardiac and skeletal muscle metabolism from fatty acid oxidation toward glucose oxidation. The metabolic shift is theoretically protective under ischemic conditions where fatty acid oxidation generates increased reactive oxygen species. Meldonium is approved in Latvia, Russia, and several former Soviet states for ischemic heart disease, chronic heart failure, and cognitive symptoms of cerebrovascular insufficiency. The compound was added to the WADA prohibited list in 2016 after widespread use in elite athletes; the Maria Sharapova case is the most prominent. Pharmacokinetics: plasma half-life 3 to 6 hours; oral bioavailability 78 percent; renally excreted. Doses are 500 to 1000 mg per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-066Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
AOD-9604

Plain-language summaryIntrigue 55 / 100

AOD-9604 is a modified fragment of the C-terminal portion of human growth hormone (residues 176-191). It was developed by Metabolic Pharmaceuticals as a fat-loss agent that retains the lipolytic effects of GH without the muscle-building effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

37/100

Failed phase 2 lipolysis candidate with modest human signal and no clear research frontier

Look, the concept behind AOD-9604 is genuinely interesting: take the C-terminal region of hGH (residues 176-191), add a tyrosine at the N-terminus, and you theoretically get the lipolytic activity of growth hormone without the IGF-1-mediated growth effects, the diabetogenic risk, or the need to suppress endogenous GH secretion. That’s a clean hypothesis. The problem is that the clinical data didn’t back it up at the level you’d need.

The Metabolic Pharmaceuticals phase 2 work showed modest weight loss and fat mass reduction in obese subjects. “Modest” is doing a lot of heavy lifting in that sentence. The compound didn’t advance because regulators and the company agreed the efficacy signal wasn’t sufficient for a marketed obesity drug. That’s not a story of a mechanism being disproven. The lipolytic activity appears real. But it is a story of a mechanism that, when translated to humans at tolerable doses, produces underwhelming effect sizes.

That historical context matters a lot right now. The fat loss peptide landscape in 2025-2026 is absolutely dominated by the GLP-1 and dual/triple incretin story. Semaglutide delivers 10-15% body weight loss in clinical practice. Tirzepatide is hitting 20%+. Retatrutide is pushing even further. Against that backdrop, “modest fat mass reduction” from a subcutaneous peptide with a plasma half-life under an hour looks very hard to justify as a primary research target. You’re working in a therapeutically crowded space where the competition has completed phase 3 trials.

What we think still has value here is the probe angle. If your research question is specifically about the structure-activity relationships of hGH C-terminal fragments, the separation of the lipolytic versus somatotropic domains, or beta-3 adrenergic receptor involvement in hGH-driven lipolysis, AOD-9604 is a legitimate tool. Thats a narrow use case, but its a real one. The short half-life is honestly a research complication more than a feature; you’re dealing with rapid clearance that makes sustained exposure studies difficult unless you’re designing specific dosing regimens around it.

The sourcing situation is standard peptide research chemical territory: multiple vendors, variable QC, standard lyophilized powder reconstitution. Nothing remarkable there. The compound doesnt have the replication problem of something like BPC-157: there are real human trials to point to, but those trials tell a story of limited clinical utility, not hidden potential. For a bench scientist trying to choose where to spend time in metabolic biology, AOD-9604 sits well below the frontier.

Novelty

28

Mechanism promise

40

In-category differentiation

30

Evidence quality

48

Translational signal

38

Research bench value

40

Rationale AOD-9604 had a coherent mechanistic hypothesis and real phase 2 clinical data, but failed to achieve regulatory-level efficacy; in a landscape now dominated by GLP-1 and multi-incretin compounds, its modest fat mass signal offers little competitive rationale for primary research focus, though narrow probe utility for hGH fragment biology remains.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Modified hGH 176-191 fragment

A modified C-terminal fragment of hGH (residues 176-191) developed for fat loss without GH metabolic effects.

Abstract

AOD-9604 (modified hGH 177-191; molecular formula C78H125N23O23S2) is a modified analog of the C-terminal fragment of human growth hormone (residues 176-191) developed by Monash University and Metabolic Pharmaceuticals. The structural modification is the addition of a tyrosine at the N-terminus relative to the unmodified 176-191 sequence. The compound was developed on the rationale that the lipolytic activity of human growth hormone resides in the C-terminal fragment, separable from the IGF-1-mediated growth-promoting and pro-diabetogenic activities. Phase 2 trials in obesity showed modest weight loss and fat mass reduction without effect on lean mass or insulin sensitivity. The compound did not advance to FDA approval; clinical efficacy was not strong enough to support marketing. The compound is sold as a research chemical/peptide. Pharmacokinetics: plasma half-life of subcutaneous AOD-9604 is short (less than 1 hour); reported doses for research-grade lipolysis applications are 250 to 500 micrograms subcutaneously daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-085Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Quercetin

Plain-language summaryIntrigue 62 / 100

Quercetin is a natural flavonoid found in onions, apples, and capers. It is one half of the dasatinib-quercetin (D+Q) senolytic combination. Quercetin alone has anti-allergic and anti-inflammatory effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

38/100

Established senolytic flavonoid with a real D+Q role but clearly outclassed by fisetin standing alone

Look, quercetin isn’t a bad compound. It’s just not a particularly exciting one right now, and the rubric rewards excitement. It’s a flavonoid you’ll find in every health food store, in onions, in apples. Researchers have been poking at it since the 1990s across allergy biology, NF-kB signaling, antioxidant assays, and a half-dozen other directions. None of those lines produced anything that made quercetin the center of a research program.

The senolytic angle changed the picture, a little. The Kirkland and Niedernhofer group’s work canonized the dasatinib-plus-quercetin (D+Q) regimen as the reference senolytic protocol, and that gave quercetin a specific, real identity in the aging research space. Small Mayo Clinic trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed hints of a signal. The protocol is being used in ongoing NIA-funded trials. Thats genuinely meaningful. What we don’t like is that quercetin is the junior partner in that combination. Dasatinib is doing the mechanistic heavy lifting on the Bcl-2 and Bcl-xL senescence survival pathways. Quercetin contributes, but isolating its contribution from dasatinib in most D+Q datasets is difficult, and its standalone senolytic potency is explicitly weaker than fisetin in head-to-head comparisons.

The pharmacokinetics are a real problem for bench work. Oral bioavailability of the free aglycone is poor, with plasma concentrations after typical oral dosing well under one percent of the administered dose. Researchers working with quercetin in cell culture or preclinical models often dose at concentrations that don’t map cleanly to anything achievable in vivo. That gap creates a reproducibility problem that the literature is quietly littered with.

On mechanism, the multi-target profile sounds appealing: mast cell stabilization, NF-kB inhibition, antioxidant activity, Bcl-family modulation. In practice, that breadth is as much a research liability as an asset. When a compound does five things at once, attributing an effect to any one of them is methodologically hard. Most of the preclinical literature leans on this ambiguity rather than resolving it.

We think quercetin has a legitimate home in any senolytic research program as a reference tool and as the Q in D+Q studies. If you’re building a senolytic protocol from scratch and you’re not running D+Q specifically, fisetin is the more defensible choice at the bench right now. Quercetin isn’t junk. It’s an established, actively-studied compound with a real but secondary role in the most important research regimen in its class, and a score in the upper-30s reflects exactly that.

Novelty

28

Mechanism promise

45

In-category differentiation

27

Evidence quality

50

Translational signal

40

Research bench value

44

Rationale Quercetin escapes the OTC food/herb cap because the senolytic indication is a real, clinically-tested research angle with Mayo Clinic trials behind it, not a generic supplement claim. Scores land in the high-30s because the compound is genuinely useful within the D+Q protocol, but on every axis it’s the weaker partner: weaker senolytic than fisetin, poor oral bioavailability, and most of the clinical signal is inseparable from dasatinib’s contribution.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Flavonoid senolytic / mast cell stabilizer

A widely distributed flavonoid with weaker senolytic activity than fisetin, often combined with dasatinib in the canonical D+Q senolytic regimen.

Abstract

Quercetin (3,3′,4′,5,7-pentahydroxyflavone; CAS 117-39-5; molecular formula C15H10O7; molecular weight 302.24) is a widely distributed flavonoid present in onions, apples, capers, and many other plants. The compound has multiple mechanisms of pharmacological interest: mast cell stabilization (anti-allergic effects), direct antioxidant activity, anti-inflammatory effects through NF-kB inhibition, and senolytic activity (in combination with the kinase inhibitor dasatinib in the canonical D+Q regimen developed by Kirkland and Niedernhofer). The senolytic activity of quercetin alone is modest; the dasatinib combination is substantially more effective. Bioavailability is poor as the free aglycone but better as the rutinose glycoside; plasma quercetin concentrations after oral dosing are typically less than 1 percent of the dose. Doses range from 500 mg to 2 grams per day; the senolytic D+Q regimen uses pulsatile dosing of 1000 to 1500 mg quercetin with 100 mg dasatinib for 2 to 3 days monthly.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-100Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
PQQ (Pyrroloquinoline Quinone)

Plain-language summaryIntrigue 60 / 100

PQQ (pyrroloquinoline quinone) is a redox cofactor found in plants and bacteria that may stimulate mitochondrial biogenesis (creation of new mitochondria). Sold as a longevity and energy supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

35/100

A mature bacterial redox cofactor with an interesting mitochondrial story that human evidence never fully validated

Look, PQQ has been in the research conversation long enough that calling it a frontier compound is a stretch. The bacterial dehydrogenase work goes back to the 1980s, and the mammalian mitochondrial biogenesis story picked up in the early 2000s after some elegant deficiency-repletion work in mice. Its a genuinely interesting setup. The problem is what happened next.

The mechanism is the compound’s strongest asset. PQQ cycles through redox states faster than vitamin C and with more catalytic capacity than most dietary antioxidants, and the downstream signaling through NRF2 and PGC-1alpha gives it more to say than just “antioxidant.” The biogenesis angle is real: chronic PQQ deficiency in rodents produces mitochondrial dysfunction phenotypes that reverse on repletion. We like that the mechanism has multiple plausible entry points, and the chemistry is genuinely unusual for a dietary-origin compound. That’s worth noting.

What we dont like: fifteen-plus years of research interest and the human trials are still small, the effect sizes modest, the replication incomplete. Cognitive function, fatigue, and cardiovascular endpoints have all been probed in small cohorts with some signal, but not the kind of signal that reorganizes a research program. The NRF2 and PGC-1alpha pathways are crowded now. Urolithin A, NAD precursors like nicotinamide riboside, and several mitochondria-targeted peptides have moved into the same territory with arguably cleaner pharmacology and stronger human translation. PQQ doesnt clearly win any dimension of that comparison.

The bench utility is real but specific. If your program involves dietary-origin redox cofactors in mitochondrial function, or probing PGC-1alpha activation by a small molecule with a plant-food sourcing history, PQQ earns its place in the toolkit. The BioPQQ trademarked product has reasonable characterization and reproducible sourcing, which matters for experimental consistency. But as a general mitochondrial biogenesis probe, theres more compelling options with cleaner pharmacology and better-defined target engagement.

Honestly, this compound fits the profile of many redox and mitochondrial-adjacent supplements that generated real excitement a decade ago and have since settled into the “interesting but unproven” column. The mechanism remains incompletely characterized, which after this many years of study is more liability than intrigue. Worth tracking for programs specifically touching dietary-origin redox biology or NRF2 activation in aging contexts, not a compound to build a research program around.

Novelty

32

Mechanism promise

45

In-category differentiation

28

Evidence quality

33

Translational signal

35

Research bench value

42

Rationale PQQ earns points on mechanism interest (NRF2 + PGC-1alpha + high-capacity redox cycling is a real multi-target story) but loses heavily on novelty (the mitochondrial biogenesis angle is fifteen-plus years old), thin human evidence with modest effect sizes, and weak differentiation in a now-crowded mitochondrial space. Bench utility exists but is narrow and not irreplaceable.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Redox cofactor

A bacterial redox cofactor and putative mitochondrial biogenesis enhancer found in trace amounts in plant foods, sold as a dietary supplement.

Abstract

Pyrroloquinoline quinone (PQQ; CAS 72909-34-3; molecular formula C14H6N2O8; molecular weight 330.21) is a redox cofactor present in bacterial dehydrogenases and in trace amounts in plant foods (kiwi, parsley, green tea, fermented soy). PQQ has been studied as a putative mitochondrial biogenesis stimulant; chronic dietary PQQ deficiency in mice produces mitochondrial dysfunction phenotypes that are reversed by repletion. The compound has been studied for cognitive function, fatigue, and cardiovascular endpoints in small human trials with modest effect sizes. Mechanism is incompletely characterized; proposed activities include direct redox cycling, NRF2 pathway activation, and PGC-1alpha-mediated mitochondrial biogenesis. Doses are typically 10 to 40 mg per day. The compound is sold as a dietary supplement (BioPQQ).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-119Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
PEG-MGF (Mechano Growth Factor)

Plain-language summaryIntrigue 65 / 100

PEG-MGF is a pegylated form of mechano-growth factor, a splice variant of IGF-1 produced in muscle in response to mechanical loading. The PEG group extends the half-life from minutes to days. Used in research for satellite cell activation and muscle repair. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

40/100

Interesting local IGF-1 splice variant biology for muscle repair, but preclinical-only with limited independent replication

The biology here is genuinely interesting. MGF (mechano growth factor) is the locally-produced splice variant of IGF-1 (IGF-1Ec) that muscles generate in response to mechanical damage. Unlike systemic IGF-1, it carries a unique 24-residue C-terminal extension produced by alternative splicing of exon 5, and that E-peptide fragment appears to activate muscle satellite cells through a mechanism that doesn’t require IGF-1 receptor engagement. Geoffrey Goldspink’s lab at UCL established most of the foundational work, and the core biology is elegant: mechanical loading triggers local MGF expression, which recruits quiescent satellite cells into the repair cycle upstream of systemic IGF-1 signaling.

Pegylation addresses the most obvious problem with native MGF, which clears from plasma in minutes. Attaching a polyethylene glycol moiety extends the half-life to hours in animal models, making sustained satellite cell engagement more pharmacologically plausible. In rodent studies, PEG-MGF has shown increased satellite cell number, improved muscle cross-sectional area after damage, and some preservation of muscle mass in aging models. The signal is real enough to take seriously at the preclinical level.

Here’s the thing though: the literature is thin and concentrated. Goldspink’s group produced a disproportionate share of the foundational MGF research, and independent replication of PEG-MGF specifically is sparse. Human data is essentially nonexistent at this point. The compound lives in the same research peptide ecosystem as BPC-157 and TB-500, and it shares those compounds’ core problem: compelling preclinical biology that hasn’t crossed into well-powered human trials. The satellite cell activation story is mechanistically cleaner than BPC-157’s polyvalent mechanism, but the evidence base is actually narrower, not wider.

What we like as a research tool: PEG-MGF is a useful probe for studying the IGF-1Ec axis specifically, and for distinguishing local vs. systemic IGF-1 effects in muscle repair models. If you’re running satellite cell biology, this compound lets you ask questions you can’t ask with systemic IGF-1 or conventional GHRPs. Thats a real niche. The E-peptide receptor question (whether it engages something distinct from IGF-1R) remains open and is genuinely worth pursuing at the bench.

What we dont like: sourcing quality is variable across the research peptide market, pegylation adds synthesis complexity that translates to real vendor-to-vendor inconsistency in purity and conjugation degree, and the dose-response relationship in rodent models isn’t cleanly established even within the existing literature. For a lab running a dedicated satellite cell or muscle repair program, PEG-MGF makes sense in vitro. For most programs, the thin and concentrated evidence base makes it a secondary priority behind compounds with broader replication behind them.

Novelty

40

Mechanism promise

58

In-category differentiation

40

Evidence quality

28

Translational signal

22

Research bench value

45

Rationale Goldspink’s UCL group produced a disproportionate share of the foundational MGF literature, and independent PEG-MGF replication is sparse; the E-peptide satellite cell activation biology is mechanistically compelling but human evidence is essentially absent, placing this compound alongside BPC-157 in the single-lab-only tier at the lower end of that range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Pegylated IGF-1 splice variant

A pegylated form of mechano growth factor (the IGF-1Ec splice variant) sold as a research peptide for muscle repair applications.

Abstract

PEG-MGF is a pegylated form of mechano growth factor (MGF), a splice variant of IGF-1 (IGF-1Ec) generated by exercise-induced muscle damage. MGF differs from systemic IGF-1 in containing a unique 24-residue C-terminal extension produced by alternative splicing of exon 5. The MGF C-terminal peptide alone (without the IGF-1 mature peptide) has been studied for muscle stem cell activation. Pegylation extends plasma half-life of the otherwise rapidly cleared peptide. The compound is sold as a research peptide; clinical evidence base in humans is sparse.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-134Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Suvorexant

Plain-language summaryIntrigue 78 / 100

Suvorexant, sold as Belsomra, is a dual orexin receptor antagonist (DORA), the first of a new sleep medication class. Unlike GABAergic hypnotics it works by blocking the wakefulness-promoting orexin system. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

First-in-class DORA with a clean mechanistic story, but the novelty window has closed

Suvorexant was genuinely exciting when Merck cleared the FDA in 2014. It was the first commercialized DORA, and that represented a clean conceptual break from the GABAergic sedative tradition that had dominated sleep pharmacology for decades. Instead of dampening CNS excitability broadly, it blocks orexin-A and orexin-B at both OX1R and OX2R, removing the active drive to wakefulness rather than forcing sedation. Thats a real mechanistic contribution, and it’s still the reason the DORA class earns serious bench attention at all.

Here’s the thing though: that novelty window is essentially closed. Suvorexant has been on market twelve years. The pivotal METEOR and SORReL trials are thoroughly characterized. Lemborexant came in with a sharper half-life profile, daridorexant demonstrated competitive tolerability data in phase 3, and suvorexant is now the reference standard in a maturing class rather than the frontier of it. The 12-hour plasma half-life driven by CYP3A4 clearance creates morning residual sedation concerns that newer entrants specifically addressed. A bench scientist choosing a DORA probe today has reasons to reach past suvorexant rather than defaulting to it.

What keeps it genuinely relevant is the orexin system’s expanding research surface beyond insomnia. The glymphatic clearance hypothesis has pulled DORAs into Alzheimer’s biology in a serious way. The Ju group at Washington University published mechanistic work suggesting orexin-driven wakefulness disrupts CSF-ISF exchange responsible for amyloid and tau clearance during sleep, making suvorexant an active tool in neurodegeneration research programs rather than just a sleep drug. That hypothesis has been tested clinically (NCT03975114 examined amyloid accumulation under DORA conditions directly). The effect size and durability aren’t established, but the question is real. Similarly, orexin’s role in reward circuitry and drug-seeking behavior has made suvorexant a useful pharmacological probe in addiction neuroscience, where blocking orexin signaling attenuates cue-induced reinstatement in preclinical models.

We think the honest framing for a research library is this: suvorexant is a high-quality reference compound for orexin biology, with excellent evidence quality for its approved indication and early-but-credible signals in neurodegeneration and addiction circuits. What we don’t love is that the most compelling orexin research right now tends to treat suvorexant as a comparator or proof-of-concept tool rather than the object of study itself. If your program is centered on orexin system biology, it’s an important reagent. If you’re hunting the frontier of the sleep-cognition-longevity space, the orexin angle is genuinely interesting but suvorexant is the well-characterized older member of a class that’s rapidly gaining better-optimized successors. Schedule IV. Research-use context only.

Novelty

35

Mechanism promise

60

In-category differentiation

45

Evidence quality

75

Translational signal

72

Research bench value

65

Rationale Suvorexant scores well on evidence and translational signal as a phase-3-backed FDA-approved drug, but twelve years post-approval its novelty is largely spent and newer DORAs (lemborexant, daridorexant) address its PK weaknesses; what keeps the score from collapsing further is the orexin system’s emerging roles in neurodegeneration and addiction, where suvorexant still functions as the reference probe.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual orexin receptor antagonist

A dual orexin receptor antagonist (DORA) FDA-approved as Belsomra for insomnia, the first commercialized of the DORA class.

Abstract

Suvorexant (Belsomra; MK-4305; CAS 1030377-33-3; molecular formula C23H23ClN6O2; molecular weight 450.92) is a dual orexin receptor (OX1R, OX2R) antagonist developed by Merck and approved by the FDA in 2014 for insomnia. The compound was the first commercialized DORA. Mechanism is competitive antagonism at orexin-A (hypocretin-1) and orexin-B (hypocretin-2) binding sites on OX1R and OX2R, attenuating orexinergic wakefulness signaling without GABAergic hypnotic effects. Pharmacokinetics: plasma half-life 12 hours; CYP3A4 metabolism. Approved doses are 5 to 20 mg at bedtime. Schedule IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-150Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnesium L-Threonate

Plain-language summaryIntrigue 58 / 100

Magnesium L-threonate is a magnesium salt designed to penetrate the blood-brain barrier better than other magnesium forms. Developed by MIT researchers and marketed as Magtein for cognitive support. Clinical evidence is limited. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

48/100

Novel CNS-delivery magnesium salt with real but consortium-narrow evidence and modest cognitive signal

The story here starts with a real scientific observation. Guosong Liu’s group at MIT showed, in a 2010 paper in Neuron, that chronically elevating brain magnesium improves synaptic density and working memory in rodents, and that standard magnesium salts don’t reliably cross into the CNS in meaningful quantities. L-threonate complexation changed that. The rodent data was compelling enough that Magtein got licensed, commercialized, and into phase 2 trials before most researchers had finished reading the paper. That’s a faster bench-to-market arc than you usually see for a magnesium salt, and it tells you the mechanism hypothesis resonated with people who fund things.

Here’s the thing though: the mechanism itself is downstream of well-understood magnesium biology. NMDA receptor co-agonism, synaptic plasticity, long-term potentiation gating. None of that is new pharmacology. What’s interesting is the delivery problem being solved, not the endpoint being targeted. Magnesium’s CNS role is established; what’s genuinely novel is the claim that you can selectively elevate brain magnesium with a specific salt when others fail at the blood-brain interface. If that claim holds up under independent replication, it’s a legitimately useful research tool. If it doesn’t, it’s just an expensive magnesium supplement with good branding.

The evidence situation is real but limited. The Liu consortium drove the preclinical work heavily, and the phase 2 trials in mild cognitive impairment produced modest, consistent improvements on cognitive endpoint measures. “Modest and consistent” is better than “massive and irreproducible,” but it doesn’t make for a screaming research case. Outside the MIT-affiliated research chain, independent replication is thin. We haven’t seen the multi-center, higher-powered trials that would make this a serious clinical story. What we have is a coherent preclinical model, a plausible delivery mechanism, and early human signal that’s real but needs substantially more work.

From a bench perspective, it carries genuine probe value. If you’re studying CNS magnesium dynamics, having a form that preferentially elevates brain magnesium without the systemic confound that dominates standard oral Mg studies is actually useful. That’s not nothing. But the research community isn’t exactly rushing to build programs around it, and the single-consortium footprint on the key papers is a flag you shouldn’t ignore when evaluating the literature.

We’d call this worth watching but not worth leading with. It scores where it scores because the underlying idea is clever, the human signal is real if modest, and the CNS bioavailability story is meaningfully differentiated from generic mineral territory. But thats not the same as saying it belongs anywhere near the top tier. The evidence base is too narrow, the mechanism serves well-understood Mg biology rather than breaking new ground, and the Liu group’s outsized authorship share on the strongest papers makes independent verification genuinely difficult to assess.

Novelty

45

Mechanism promise

55

In-category differentiation

55

Evidence quality

40

Translational signal

42

Research bench value

48

Rationale Scores as novel-promising because the L-threonate complexation angle is genuinely differentiated from generic magnesium salts and the CNS bioavailability hypothesis is mechanistically coherent; held back by single-consortium evidence dominance and an endpoint mechanism (NMDA/synaptic plasticity) that is well-understood rather than frontier biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Magnesium salt of L-threonate

A proprietary magnesium salt (Magtein) with claimed superior CNS bioavailability for cognitive applications.

Abstract

Magnesium L-Threonate (Magtein; CAS 778571-57-6) is a proprietary magnesium salt developed at MIT by Guosong Liu’s group, complexing magnesium with two molecules of L-threonate (a vitamin C metabolite). The complex was designed for CNS delivery; rodent studies showed elevated brain magnesium levels and synaptic density improvements with chronic supplementation, distinguishing it from other magnesium salts which produce less reliable CNS magnesium elevation. Phase 2 trials in mild cognitive impairment have shown modest but consistent improvements in cognitive endpoint measures. Doses are typically 1 to 2 grams of the salt per day (providing 100 to 200 mg elemental magnesium). The compound is sold as Magtein-branded products and generic equivalents.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-167Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-Tryptophan

Plain-language summaryIntrigue 50 / 100

L-tryptophan is the essential amino acid precursor to serotonin and melatonin. Supplementation is sometimes used for sleep and mood, though 5-HTP (one biosynthetic step closer to serotonin) is often preferred. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic amino acid

30/100

Fully mapped serotonin precursor with modest human signal and no frontier research value

Look, L-tryptophan is a perfectly fine amino acid. It’s essential, it’s the rate-limiting substrate for serotonin biosynthesis via tryptophan hydroxylase, and it flows downstream into melatonin and through the kynurenine pathway toward NAD+. That’s real, interesting biology. The problem is we’ve known all of it for fifty years, and the research conversation moved past basic tryptophan supplementation a long time ago.

If you’re interested in serotonin precursor loading, 5-HTP bypasses the tryptophan hydroxylase rate-limit entirely and delivers substrate more efficiently. If you want to study sleep architecture, melatonin is a more precise tool. If you’re actually in the kynurenine/IDO pathway story, which is genuinely interesting in inflammation and oncology right now, you’re not supplementing tryptophan. You’re working with IDO1 inhibitors, measuring kynurenine-to-tryptophan ratios as biomarkers, or characterizing AhR signaling from bacterially derived indoles. Tryptophan as a supplement isn’t how you answer those questions.

The LNAA competition problem is a real constraint that adds a variable to any protocol. Leucine, isoleucine, valine, phenylalanine, and tyrosine all compete at the BBB transporter. The carbohydrate co-administration trick works, but it’s inelegant and confounds anything you’re trying to isolate. More precise precursors exist for every downstream target.

We’re not dismissing the human evidence. There’s a solid body of RCT data on tryptophan for sleep onset latency and depressed mood, some of it dating back to the 1970s and 1980s. Effect sizes are modest but consistent enough to take seriously. The 1989 EMS outbreak from contaminated Showa Denko product muddied the clinical risk calculus considerably; modern pharmaceutical-grade material resolved the safety question, but it reset how cautiously prescribers approach it.

What tryptophan does have is genuine bench utility in specific contexts. Studying serotonin/melatonin synthesis kinetics, modeling kynurenine pathway flux under inflammatory conditions, gut-brain axis work where commensal bacteria metabolize dietary tryptophan into indoles that signal through AhR and modulate mucosal immunity. Thats a legitimately active research direction. But the compound of interest in those protocols is usually tryptophan as a dietary variable or metabolic substrate, not as a supplemented agent in the way this library typically frames things.

For a research library oriented toward frontier targets, L-tryptophan lands firmly in the interesting-but-already-answered category. The mechanism is fully mapped, the alternatives perform better in every primary application, and the novelty dial is essentially at zero. We carry it because foundational molecules belong in a complete library and because specific biosynthesis pathway work does call for it. We dont see it as a priority research target for investigators working at the front of anything currently active.

Novelty

18

Mechanism promise

25

In-category differentiation

20

Evidence quality

55

Translational signal

45

Research bench value

28

Rationale Tryptophan scores low on novelty and differentiation because the mechanism is completely understood and more efficient substrate tools exist for every downstream application; evidence and translational scores are moderate given genuine multi-decade RCT literature on sleep and mood, but those axes carry less weight and the calculated overall of 30 stays within the basic-aa cap without triggering it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Essential aromatic amino acid

An essential aromatic amino acid precursor of serotonin, melatonin, and niacin; supplemented for sleep and mood applications.

Abstract

L-Tryptophan (CAS 73-22-3; molecular formula C11H12N2O2; molecular weight 204.23) is an essential aromatic amino acid and the precursor of serotonin, melatonin, and (via niacin) NAD+. Tryptophan hydroxylase is the rate-limiting enzyme in serotonin biosynthesis; supplementation can increase substrate availability when the enzyme is operating below saturation. The compound has been used for sleep, depression, and anxiety with modest efficacy. Bioavailability is reduced by competing large neutral amino acids (LNAAs); taking tryptophan with carbohydrate (which raises insulin and lowers competing LNAAs) improves CNS uptake. Doses are typically 500 mg to 2 grams per day. The 1989 EMS (eosinophilia-myalgia syndrome) outbreak from contaminated L-tryptophan led to FDA restrictions; modern products are pharmaceutical grade.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-183Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Nicotine

Plain-language summaryIntrigue 70 / 100

Nicotine is the principal alkaloid of tobacco. Beyond its association with smoking, pure nicotine has cognitive enhancement effects via nicotinic acetylcholine receptor agonism. Pouches and gums isolate the cognitive effects from the carcinogenic combustion products of cigarettes. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Mature nAChR agonist with modest cognitive signal; better probes now exist for most research questions

Nicotine is one of the most studied small molecules in the history of pharmacology. That’s not a compliment in a research library context. When a compound appears in roughly 30,000 indexed papers, has been continuously characterized since the early 20th century, and carries multiple approved NRT formulations, the question isnt “is this interesting” but “what is left to learn, and can we learn it from nicotine specifically.”

The mechanism is genuinely complex, and we’ll give it that. Nicotine engages nAChRs across subunit compositions: high-affinity binding at alpha4-beta2 receptors that dominate cortical tissue and drive most of the attentional signal, moderate affinity at alpha7 receptors where the neuroinflammation and neuroprotection story lives, and peripheral autonomic effects through alpha3-containing subtypes. That broad profile is actually part of why nicotine has persisted as a research subject. But here’s the problem: if you want to dissect the contribution of a specific subunit to a cognitive or inflammatory endpoint, you now have tools like GTS-21 and PNU-282987 for alpha7, or varenicline’s well-characterized partial agonism at alpha4-beta2. Nicotine is the blunt hammer. Selectivity has moved past it.

The cognitive enhancement literature is honest and modest. Multiple replicated crossover designs in non-smokers, including several decent meta-analyses, confirm small but consistent improvements in sustained attention and working memory at 1 to 4 mg via gum or lozenge. Effect sizes are real, replication is solid, the translational arrow is intact. What we dont have is any signal that nicotine does something clinically meaningful that isnt better addressed by a more selective probe, or that it opens a biological question that other tools cant answer.

For Alzheimer’s research, there was a period when the nicotinic hypothesis got real traction. Loss of alpha4-beta2 receptor density in AD cortex is well-documented, and early patch studies in mild cognitive impairment showed some signal. That work has largely been handed to more selective partial agonists, and nicotine itself doesnt occupy a special position in those programs anymore. The alpha7 neuroinflammation angle is arguably more alive, but again, the selectivity issue applies.

We think nicotine earns its place in a reference library when the question specifically requires broad nAChR engagement that mirrors realistic physiological or tobacco-adjacent exposure conditions. As a compound to prioritize in a forward-looking research program targeting cognitive enhancement or neuroprotection, the effect-size-to-literature-depth ratio is deeply unfavorable. The story is mostly written. Serious investigators in 2025 who want to probe nicotinic biology have sharper tools, and that’s what drives the score here.

Novelty

22

Mechanism promise

30

In-category differentiation

28

Evidence quality

65

Translational signal

55

Research bench value

42

Rationale Nicotine scores low on novelty and differentiation because it is one of the most pharmacologically characterized small molecules in existence, with more selective subtype-specific probes now available for serious bench work; evidence quality and translational signal are real but serve to confirm a well-understood story rather than open new questions.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Nicotinic acetylcholine receptor agonist

A pyridine alkaloid from tobacco (Nicotiana spp.) with broad nicotinic acetylcholine receptor agonist activity, studied at low doses for cognitive enhancement.

Abstract

Nicotine (CAS 54-11-5; molecular formula C10H14N2; molecular weight 162.23) is a pyridine alkaloid present principally in Nicotiana tabacum and other Solanaceae species. The compound is a potent agonist at nicotinic acetylcholine receptors (nAChRs) with affinity that varies by subunit composition: alpha4-beta2 nAChRs (high abundance in CNS) at high affinity, alpha7 nAChRs at moderate affinity, alpha3-containing autonomic nAChRs at moderate affinity. Low-dose nicotine has been studied extensively for cognitive enhancement (improved attention, working memory) in non-smokers; effect sizes are modest but consistent. Smoking cessation pharmacotherapy uses nicotine replacement (gum, patch, lozenge, inhaler, nasal spray) at doses sufficient to relieve withdrawal but lower than typical cigarette smoking exposure. The compound is highly addictive when delivered through rapid-onset routes (smoking, vaping); slower-onset routes (gum, patch) have lower abuse liability. Doses for cognitive applications are typically 1 to 4 mg via gum or lozenge.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-198Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 46 47 48 49 50 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.